Evaluation of Participation Data in the Context of Cancer Prevention
Author(s)
Réka Vajda, BSc, MSc, PhD1, Annamaria Pakai, MSc, RN, PhD2, Zsuzsanna Kívés, BSc, MSc, PhD1, Imre Boncz, MSc, PhD, MD1.
1Institute for Health Insurance, University of Pécs, Pécs, Hungary, 2Institute of Emergency Care, Pedagogy of Health and Nursing Sciences, University of Pécs, Pécs, Hungary.
1Institute for Health Insurance, University of Pécs, Pécs, Hungary, 2Institute of Emergency Care, Pedagogy of Health and Nursing Sciences, University of Pécs, Pécs, Hungary.
OBJECTIVES: Malignant diseases are a leading problem worldwide. Female breast cancer is the most frequently diagnosed tumor type, while cervical malignant tumors rank fourth among diseases affecting women. Screening examinations occupy a special place in the history of Hungarian health policy. There is a close correlation between mortality rates and screening characteristics. We assess the participation indicators of breast and cervical screening activities conducted between 2010-2023.
METHODS: We conducted a retrospective, quantitative, descriptive data analysis. The data included in the analysis originate from the National Health Insurance Fund's financing database and cover the period between 2012-2023. For breast screening, we used the mammographic screening code (OENO: 42400) to determine screening coverage, and diagnostic examination codes (OENO: 31930, 31931, 31932, 31933, 31934, 31936) to determine diagnostic examination coverage. The coverage is the proportion of women who participated in mammographic breast examinations for either screening or diagnostic purposes. Regarding cervical screening indicators, We analyzed both diagnostic (OENO: 29602) and screening-purpose (OENO: 42600, 42700) cytological examinations. In addition to these, we calculated averages, absolute and relative frequencies, and 95% confidence intervals (CI).
RESULTS: The coverage of breast screening (screening coverage + diagnostic examination coverage combined) between 2012-2023 was 56.9%. Screening coverage decreased from 15.0% (95% CI (14.6-15.3%)) to 12.3% (95% CI (10.9-13.7%)), while diagnostic examination coverage decreased from 42.0% (95% CI (41.2-42.7%)) to 35.1% (95% CI (31.8-38.5%)). Regarding cervical screening, the number of patients and participation rates for diagnostic cytological examinations decreased during the studied period. The added value of screening cytology is moderate, with participation willingness also being low.
CONCLUSIONS: Breast and cervical screening, meeting the expectations for screening examinations, are proven to be effective in detecting diseases in their pre-cancerous state. Our country has made efforts to intensify the fight against cancer; however, there are always untapped reserves in cancer screening.
METHODS: We conducted a retrospective, quantitative, descriptive data analysis. The data included in the analysis originate from the National Health Insurance Fund's financing database and cover the period between 2012-2023. For breast screening, we used the mammographic screening code (OENO: 42400) to determine screening coverage, and diagnostic examination codes (OENO: 31930, 31931, 31932, 31933, 31934, 31936) to determine diagnostic examination coverage. The coverage is the proportion of women who participated in mammographic breast examinations for either screening or diagnostic purposes. Regarding cervical screening indicators, We analyzed both diagnostic (OENO: 29602) and screening-purpose (OENO: 42600, 42700) cytological examinations. In addition to these, we calculated averages, absolute and relative frequencies, and 95% confidence intervals (CI).
RESULTS: The coverage of breast screening (screening coverage + diagnostic examination coverage combined) between 2012-2023 was 56.9%. Screening coverage decreased from 15.0% (95% CI (14.6-15.3%)) to 12.3% (95% CI (10.9-13.7%)), while diagnostic examination coverage decreased from 42.0% (95% CI (41.2-42.7%)) to 35.1% (95% CI (31.8-38.5%)). Regarding cervical screening, the number of patients and participation rates for diagnostic cytological examinations decreased during the studied period. The added value of screening cytology is moderate, with participation willingness also being low.
CONCLUSIONS: Breast and cervical screening, meeting the expectations for screening examinations, are proven to be effective in detecting diseases in their pre-cancerous state. Our country has made efforts to intensify the fight against cancer; however, there are always untapped reserves in cancer screening.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH94
Topic
Epidemiology & Public Health, Health Policy & Regulatory, Health Service Delivery & Process of Care
Topic Subcategory
Public Health
Disease
Oncology